On my blog today bkoffman.blogspot.com I share my ASH interview with Dr. Sharman where we discussed the data on FCR versus BR.
While this is less the exciting news it would have been a few years back before the emerging era of targeted therapies,, it is still important for a significant segment of us who will need or chose chemo-immunotherapy.
In my preamble to the video, I go over my thoughts on this subject.
My prior post was on the topic of CLL being the "good cancer".
I will be traveling for the new two weeks so won't be readily available by email.